Portal de Murcia
www.portaldemurcia.com
The research group in Oncology Multidisciplinary UCAM directed by Dr. Antonio Brugarolas Masllorens responsible for the Platform for Oncology Chiron Hospital of Torrevieja, and researchers Ramon Gonzalez Manzano, Bethlehem Valenzuela Jimenez and Manuel Sureda, doctors of the same unit, they work in a genetically based to detect the most effective drug treatment for each patient.
This group of researchers is a pioneer in our country in the use of the technique to detect RNA Tumor gene profile in response to a drug.
In just two weeks you can get results on compounds that would be more effective personalized treatment in solid tumors in adults, the most common so far, says the researcher.
This new formulation allows reducing the toxicity of chemotherapy treatments traditionally employed, as it would be necessary to combine different drugs, that affect both the vitality and appearance of the patient, to achieve a coverage limited efficacy to 50% or 60%.
"With less drugs and more successful, as they act in a targeted manner to the tumor without significantly affecting other healthy areas, you can get a hit rate of 90% to fight the disease," says the director.
Right now, "almost half of the people who are receiving traditional chemotherapy, are supplied with a lower percentage of medication that his body could tolerate" says Dr. Brugarolas.
This advance allows to adjust the permissible dose for each individually affected, significantly improving the quality and treatment time.
The drugs are metabolized differently by each patient, you can adjust the dose and get a 20% improvement in their response to the drug, he concludes.
The personalized approach to cancer improves the quality of life of patients suffering from this disease, contraindications selecting treatments that we use;
"We can avoid drugs that agredan organ already weakened hair or cancer patients fall," says the principal investigator.
Source: UCAM
Privacy policy
- Legal notice
- Cookies